News
Market and company headlines
KRYSAll
Loading
08:00-16:00Oct 222 Stories
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market capitalization of
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcas
10:00Oct 161 Story
09:00-11:00Oct 152 Stories
Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin
Krystal Biotech, Inc. (NASDAQ:KRYS) reported preliminary clinical findings from a pilot study of KB113, an investigational intratumoral immunotherapy being developed for patients with Gorlin syndrome, showing regression in more than 80% of assessed basal cell carcinoma (BCC) lesions.
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.
07:00-09:00Oct 152 Stories
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect KB113 injections were well tolerated by Gorlin syndrome patients; all reported adverse events were mild to moderate in severity and transient in nature Data will be presented by study investigator Dr. Shireen Guide at the 14th PeDRA Annual Conference, October 15-17, 202
03:00Oct 151 Story
02:00-06:00Oct 102 Stories
Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)
Krystal Biotech is downgraded from Buy to Hold as U.S. VYJUVEK sales plateau and growth shifts ex-U.S. Read more on KRYS stock here.
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value
Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on KRYS stock here.
08:00-13:00Oct 82 Stories
What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders
Krystal Biotech’s VYJUVEK gene therapy for dystrophic epidermolysis bullosa has already delivered strong commercial traction, generating high revenue and robust gross margins in chronic use. The therapy’s specialized manufacturing process, treatment experience, and recurring revenue model have created a meaningful competitive moat, even as European pricing negotiations and emerging rivals introduce new uncertainties. Next, we’ll explore how VYJUVEK’s high-margin, recurring revenue profile...
Why Krystal Biotech (KRYS) Is Drawing Fresh Attention
Krystal Biotech (KRYS) is drawing fresh attention after news that its VYJUVEK gene therapy for dystrophic epidermolysis bullosa has gained commercial traction, supported by high revenue, strong gross margins, and recurring treatment demand. Recent trading shows a mixed picture for Krystal Biotech. The share price has eased about 9% over the past month and roughly 13% over the last quarter, yet the year-to-date share price return of 31.45% and 1-year total shareholder return of 73.40% point to...
07:00Oct 81 Story
07:00Oct 61 Story
23:00Oct 51 Story
13:00Sep 251 Story
04:00Sep 241 Story
09:00Sep 211 Story
12:00Sep 101 Story
11:00Sep 32 Stories
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
08:00Sep 31 Story
12:00Sep 21 Story
01:00Aug 281 Story
15:00Aug 251 Story
07:00Aug 221 Story
07:00-12:00Aug 142 Stories
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says
Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blis
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.
06:00Aug 141 Story
12:00-22:00Aug 102 Stories
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
VYJUVEK revenue surged 24% as the company eyes a multiproduct pipeline transition.
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annualized basis producing an average annual return of 42.63%. Currently, Krystal Biotech has a market capitalization of